ALK and non-small cell lung carcinoma: Next generation ALK TKIs, such as alectinib and brigatinib, showed superior efficacy in the primary treatment of ALK‐positive NSCLC compared with crizotinib.10, 11 However, as shown in Figure 1, the PFS of patients who received next‐generation ALK‐TKIs tailored to secondary mutations is relatively short, and the PFS of patients receiving next‐generation ALK‐TKIs in first‐line treatment is expected to be long.